hormone and radiation therapy in high- and very high-risk patients with prostate cancer
Article Quality & Performance Metrics
Readership in this journal
SteadyRanked #34 of 50 articles by views in supportive care in cancer
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
Abstract
The prevalence of prostate cancer (PC) is steadily growing every year. In the Russian Federation, its peak morbidity is in the age group of 70 years. Some patients refuse surgery or have contraindications because of comorbidity. Teleradiotherapy in combination with or without hormone therapy is an alternative treatment. The paper analyzes the authors’ results of treating high- and very high-risk patients with PC who received hormone and radiation therapy. The study retrospectively included the data of 132 patients who had been allocated to 3 groups according to the duration of adjuvant hormone therapy. The treatment results were assessed over a 5-year follow-up period according the following parameters: a lower decreased prostate-specific antigen (PSA) score, recurrence rate, and 5-year relapse-free survival determined the by PSA level.
| Reference Key |
karyakin2014onkourologihormone
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;A. O. Karyakin;Yu. V. Gumenetskaya;N. A. Gorban;N. G. Minayeva;O. B. Karyakin |
| Journal | supportive care in cancer |
| Year | 2014 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.